In HCC, the literature presents conflicting evidence: Some studies report KDM6A downregulation correlated with enhanced tumorigenesis and treatment resistance, while others describe increased expression in tumor tissues [38, 39]. This evidence concerns the gene KDM6A and hepatocellular carcinoma.